CUOMO, ONOFRIO
 Distribuzione geografica
Continente #
NA - Nord America 115
EU - Europa 102
AS - Asia 47
SA - Sud America 20
AF - Africa 3
Totale 287
Nazione #
US - Stati Uniti d'America 111
IT - Italia 63
SG - Singapore 28
BR - Brasile 18
DE - Germania 12
CN - Cina 6
FI - Finlandia 6
NL - Olanda 6
GB - Regno Unito 5
VN - Vietnam 4
IN - India 3
SE - Svezia 3
CA - Canada 2
CZ - Repubblica Ceca 2
RU - Federazione Russa 2
AR - Argentina 1
BD - Bangladesh 1
DZ - Algeria 1
FR - Francia 1
ID - Indonesia 1
IQ - Iraq 1
IR - Iran 1
LB - Libano 1
MA - Marocco 1
MX - Messico 1
PL - Polonia 1
PY - Paraguay 1
TR - Turchia 1
TT - Trinidad e Tobago 1
UA - Ucraina 1
ZA - Sudafrica 1
Totale 287
Città #
Dallas 17
Chandler 16
Singapore 15
Carbonia 12
Munich 11
Chicago 10
Ashburn 6
Hefei 5
London 5
Turku 5
Ercolano 4
Santa Clara 4
Lawrence 3
Paola 3
Princeton 3
Rome 3
Afragola 2
Delhi 2
Gesuiti 2
Ho Chi Minh City 2
Olomouc 2
Reggio Calabria 2
San Nicola Manfredi 2
São Paulo 2
Alvorada 1
Balıkesir 1
Barra de São Francisco 1
Baturité 1
Beirut 1
Benevento 1
Biên Hòa 1
Boardman 1
Brasília 1
Caicó 1
Chaguanas 1
Charlotte 1
Chortkiv 1
Ciudad del Este 1
Cleveland 1
Cosenza 1
Crestview 1
Dolores Hidalgo 1
Ezeiza 1
Hanoi 1
Helsinki 1
Indian Trail 1
Jacarezinho 1
Jinhua 1
Johannesburg 1
Lajeado 1
Manaus 1
Memphis 1
Milan 1
Montreal 1
Mosul 1
Naples 1
New Delhi 1
Niterói 1
Norwich 1
Nuremberg 1
Osasco 1
Padang 1
Palermo 1
Petrópolis 1
Pittsburgh 1
Ponto Belo 1
San Francisco 1
Seattle 1
St Petersburg 1
Stockholm 1
Taubaté 1
Tizi Ouzou 1
Torres 1
Ubá 1
Votuporanga 1
Warsaw 1
Wilmington 1
Totale 191
Nome #
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study 89
miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review 74
Autoimmune colitis and neutropenia in adjuvant anti-PD-1 therapy for malignant melanoma: efficacy of Vedolizumab, a case report 50
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study 46
The antiepileptic drug levetiracetam suppresses non-convulsive seizure activity and reduces ischemic brain damage in rats subjected to permanent middle cerebral artery occlusion 41
Totale 300
Categoria #
all - tutte 2.149
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.149


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211 0 0 0 1 0 0 0 0 0 0 0 0
2021/202219 0 0 0 1 1 0 1 1 9 6 0 0
2022/202346 6 6 1 2 7 4 0 3 9 3 3 2
2023/202443 19 4 4 1 2 7 0 0 0 0 3 3
2024/2025124 7 3 1 5 8 14 6 3 10 2 32 33
2025/202667 13 17 34 3 0 0 0 0 0 0 0 0
Totale 300